Horizon Europe · Europäische Union

Development of cell-free protein synthesis platforms for discovery and/or production of biologicals

Offen

Das EU-Programm Horizon Europe plant 4 Förderungen mit 6 Mio. € – 8 Mio. € pro Projekt bei einem Gesamtbudget von 24,5 Mio. €. Die Einreichungsfrist endet am 17. Februar 2027 (EU-Ausschreibungen enden meist um 17:00 Uhr Brüsseler Zeit). Organisationen aus EU-Mitgliedstaaten und assoziierten Ländern wie der Türkei können in der Regel teilnehmen; maßgeblich sind die Bedingungen des Topics.

Frist: 17. Februar 2027 (in 94 Tagen)
Fördersumme: 6 Mio. € – 8 Mio. € pro Projekt
Gesamtbudget: 24,5 Mio. €
Förderquote: 100 % der förderfähigen Kosten Standardregel des Programms; die Ausschreibung kann abweichen.
Gesamtbudget: 24,5 Mio. €
Erwartete Förderungen: 4
Maßnahmentyp: HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
Wahrscheinliche Antragstellende: Unternehmen, KMU / Start-ups, Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber: Horizon Europe (HORIZON)
Referenz: HORIZON-HLTH-2027-01-IND-01
Ausschreibung: HORIZON-HLTH-2027-01
Zuletzt geprüft: 14. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Erwartete Ergebnisse

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals.

• Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care.

• Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals.

Umfang

Cell-Free Protein Synthesis (CFPS) has been employed in fundamental biological research for decades, however, interest for the approach as a viable means for drug development and production has only emerged in recent years. The advantages that CFPS provides in terms of efficiency, simplicity, flexibility, cost- and time savings outweigh the hurdles that are still to be overcome for CFPS to become a routine manufacturing system for peptide- or protein-based biologicals.

Currently, there are several CFPS systems used that are either based on prokaryotic or eukaryotic cell lysates (including mammalian) or fully synthetic systems consisting of all the molecular machinery necessary to create functional proteins. The choice of a specific lysate is dictated by the target protein and the end-use application. Proteins that require post-translational modification are generally produced using lysates of mammalian cells. Hence systems based on mammalian cells are of particular interest as they combine properties inherent to eukaryotic cells and their ability to produce human-like glycosylated proteins with the advantages of cell-free synthesis. These proteins include antibody fragments, antigens, virus-like particles, cytokines, enzymes, antimicrobial peptides and proteins containing non-natural amino acids. The benefits of CFPS are manifold, from ease of handling and scalability, on-demand launch of production, ability to rapidly switch products, simplified purification to facilitated standardisation and quality control. CFPS needs less energy resources, the manufacturing footprint is less complex and smaller than in cell cultivation and it enables production of proteins that have toxic effects on cells. In addition, CFPS has the potential as an enabling technology for personalised medicines and is amenable to decentralised manufacturing. CFPS has gained even more interest in the recent past owing to advances in synthetic biology and thanks to the rise of Machine-Learning/Artificial Intelligence (ML/AI). The use of generative deep learning and artificial intelligence has high potential in the de-novo design of biomolecules with specific properties of therapeutic and/or preventive nature. CFPS offers here great opportunities to increase the throughput in screening of the de-novo created biomolecules.

Vollständigen Text lesen

The application of synthetic biology, potentially also combined with generative AI, and cell-free biosynthesis open up new avenues for the design, discovery and manufacture of therapeutics not only against infectious diseases, but also non-communicable diseases and equally for vaccines.

Proposals should address at least two of the following elements:

• Address the bottlenecks that currently hamper the large-scale deployment of CFPS, i.e. the lack of a quality-by-design approach, the need to fully characterise the underlying cell lysates and their critical quality attributes and the need for better understanding of the correlations between specific cell lysate…

Wer kann sich bewerben?

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Basic medicine Basic pharmacology Health-related biotechnology Medical biotechnology Pharmaceutical development cell-free protein synthesis

Zeitplan

Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

So bewerben Sie sich

Lesen Sie das vollständige Topic im Portal: erwartete Ergebnisse, Umfang, Maßnahmentyp und die Teilnahmebedingungen einschließlich Länder- oder Konsortialvorgaben.
Registrieren Sie jede Partnerorganisation im EU Funding & Tenders Portal, um einen PIC zu erhalten.
Verbundprojekte in Forschung und Innovation benötigen in der Regel mindestens drei unabhängige Partner aus drei verschiedenen EU-Mitgliedstaaten oder assoziierten Ländern. Prüfen Sie die Regel für dieses Topic.
Bereiten Sie Teil A (Verwaltungsformulare und Budget im Portal) und Teil B (technische Beschreibung auf der offiziellen Vorlage für diesen Maßnahmentyp) vor.
Reichen Sie vor dem Fristende am Stichtag im Portal ein. Verspätete Anträge werden nicht angenommen.

From the call text

Who can apply: Not stated in the call text we hold — check the official page
Company stage: Not stated in the call text we hold — check the official page
Single applicant or consortium: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where applicants must be based: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where to apply: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

EU-Leitfaden zur Antragstellung lesen

Offizielle Quellen

Offizielle Ausschreibungsseite

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 14. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.